硫代硫酸钠(Sodium Thiosulfate) - 在研适应症：耳毒性，消毒剂，中毒_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Monosulfanemonosulfonic acid、Sodium Aurotiosulfate、Sodium Thiosulfate Hydrate

+ [12]

靶点-

作用机制

硫原子供体

治疗领域

耳鼻咽喉疾病其他疾病肿瘤+ [1]

在研适应症

耳毒性消毒剂中毒+ [2]

非在研适应症

钙化防御

原研机构

Nichi-Iko Pharmaceutical Co., Ltd.

在研机构

Kenei Pharmaceutical Co Ltd.

Decibel Therapeutics, Inc.

天津金耀药业有限公司

+ [4]

非在研机构

U.S. Army War College

最高研发阶段批准上市

首次获批日期

日本 (1984-05-11),

中毒

最高研发阶段(中国)批准上市

特殊审评孤儿药 (欧盟)、快速通道 (美国)、突破性疗法 (美国)、优先审评 (中国)

登录后查看时间轴

结构

分子式H2O3S2

InChIKeyDHCDFWKWKRSZHF-UHFFFAOYSA-N

CAS号13686-28-7

查看全部结构式(2)

关联

65

项与硫代硫酸钠相关的临床试验

NCT06672822 / Not yet recruiting临床2期IIT

An Open Label Evaluation of Intralesional Injection of Sodium Thiosulfate in the Treatment of Cutaneous or Tendon Calcinosis in Connective Tissue Disease

The specific objective of this study is to perform a small, open-label study to assess the safety and efficacy of intralesional, subcutaneous injection of STS on calcinosis symptoms and lesion size in systemic sclerosis (SSc), mixed connective tissue disease (MCTD) and dermatomyositis (DM) patients. Injection will be guided by ultrasound, lesion size assessed by ultrasound, and symptom burden by patient-reported outcome measures.

开始日期2024-12-01

申办/合作机构

University of Pittsburgh

[+1]

CTIS2023-510255-34-00 / Not yet recruitingIIT

A prospective, multi-centre, open-label, investigator-initiated randomised controlled study investigating calcinosis cutis in patients with systemic sclerosis undergoing treatment with sodium thiosulfate assessed by novel biomarkers and diagnostic imaging

开始日期2024-05-22

申办/合作机构

Århus Universitetshospital

TCTR20240520004 / Not yet recruiting临床3期IIT

Efficacy of intratympanic sodium thiosulfate gel injection to preventisplatin-induced ototoxicity: a randomized controlled trial

开始日期2024-05-20

申办/合作机构-

100 项与硫代硫酸钠相关的临床结果

登录后查看更多信息

100 项与硫代硫酸钠相关的转化医学

登录后查看更多信息

100 项与硫代硫酸钠相关的专利（医药）

登录后查看更多信息

1,309

项与硫代硫酸钠相关的文献（医药）

2024-12-01·European Journal of Surgical Oncology

Acute kidney injury after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy - A systematic review

Review

作者: Solanki, Sohan Lal ; Bhatt, Aditi ; Kuberkar, Deepali V ; Gangakhedkar, Gauri ; Kuberkar, Deepali V. ; Salunke, Bindiya ; Ambulkar, Reshma

The use of nephrotoxic chemotherapeutic agents during hyperthermic intraperitoneal chemotherapy (HIPEC), carries the risk of postoperative acute kidney injury (AKI). The available evidence on this subject is sparse with variability in the reported incidence of AKI. In this systematic review, the aim was to analyse the incidence, risk factors, and preventive measures for AKI after cytoreductive surgery and HIPEC. A systematic literature search was conducted using the terms 'Acute kidney injury', 'Acute kidney failure', 'Acute renal failure', 'Acute renal impairment', 'HIPEC Surgery', 'Cytoreductive Surgery', 'Heated Chemotherapy' on PubMed, Scopus, clinical trial.gov, POPLINE and Google Scholar. Randomized controlled trials, cohort studies and observational studies published from January 2000-December 2020 were included. The systematic review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42021247781). Data from 16 articles, which included 1622 patients, was included. The incidence AKI by any definition, was 23.36 %. The highest incidence of AKI (45.45 %) was reported after paclitaxel-HIPEC. The incidence of AKI after cisplatin-HIPEC was 34.7 %. Cisplatin HIPEC was the most common factor associated with AKI in 7/16 studies followed by pre-existing comorbidities and low intraoperative diuresis in 4 and 3 studies respectively. The perioperative use of sodium thiosulfate and amifostine led to a significant reduction in the incidence of AKI. The reported incidence of AKI after CRS-HIPEC is high. Identifying preoperative risk factors, optimising comorbidities, maintaining perioperative haemodynamic stability, perioperative use of sodium thiosulfate, maintaining adequate diuresis could reduce the incidence of AKI.

2024-12-01·Marine Pollution Bulletin

Detoxification effect of sodium thiosulfate on cadmium poisoning in Litopenaeus vannamei and the mechanisms of intestinal flora regulation

Article

作者: Wang, Xuejie ; Hou, Danqing ; Gao, Shan ; Sun, Chengbo ; Li, Ting ; Dong, Jiaxin ; Yu, Jianbo

Cadmium (Cd) is currently one of the heavy metals with the highest environmental toxicity impact. Sodium thiosulfate (Na₂S₂O₃) is a commonly used heavy metal detoxification drug in clinical practice, however, it has not been used for Cd detoxification of Litopenaeus vannamei. The present study used exposure of L. vannamei to 150 μg/L of Cd while mitigating in the addition of 75 μg/L of Na₂S₂O₃ for 28 days. The goal was to study the detoxifying effect of Na₂S₂O₃ on L. vannamei poisoning and its role in intestinal flora. The results showed that the growth of Cd group was inhibited, and the growth rate and weight gain of Cd + ST group were greater than that of Cd group. The function and structure of L. vannamei intestinal microorganisms were significantly changed under Cd stress. This work reveals that Na₂S₂O₃ can mitigate the damage caused by this concentration to L. vannamei to a certain extent.

2024-12-01·Bioresource Technology

Comparative analysis of sulfur-driven autotrophic denitrification for pilot-scale application: Pollutant removal performance and metagenomic function

Article

作者: Jiang, Yu ; Du, Jing ; Cui, Peng ; Zou, Lei ; Ma, Min ; Li, Chaoyu ; Wan, Nianhong

Two parallel pilot-scale reactors were operated to investigate pollutant removal performance and metabolic pathways in elemental sulfur-driven autotrophic denitrification (SDAD) process under low temperature and after addition of external electron donors. The results showed that low temperature slightly inhibited SDAD (average total nitrogen removal of ∼4.7 mg L^-1) while supplement of sodium thiosulfate (stage 2) and sodium acetate (stage 3) enhanced denitrification and secretion of extracellular polymeric substances (EPS), leading to the average removal rate of 0.75 and 1.01 kg N m^-3 d^-1, respectively with over twice higher total EPS. Correspondingly, nitrogen and sulfur related microbial metabolisms especially nitrite reductase and nitric oxide reductase encoding were promoted by genera including Thermomonas and Thiobacillus. The variations revealed that extra sodium acetate improved denitrification and enriched more SDAD-related microorganisms compared with sodium thiosulfate, which potentially catalyzed the refinement of practical strategies for optimizing denitrification in low carbon to nitrogen ratio wastewater treatment.

93

项与硫代硫酸钠相关的新闻（医药）

2024-11-13

·GlobeNewswire-Health Care

Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the 15th Annual Craig-Hallum Alpha Select Conference. The Company's management will be available for one-on-one meetings throughout the event. Conference Details: Event: 15th Annual Craig-Hallum Alpha Select ConferenceDate: November 19, 2024Location: Sheraton New York Times Square Hotel, New York City About Fennec PharmaceuticalsFennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. For more information, please visit www.fennecpharma.com. For further information, please contact: Investors:Robert AndradeChief Financial OfficerFennec Pharmaceuticals Inc.+1 919-246-5299 Corporate & Media:Lindsay Rocco Elixir Health Public Relations+1 862-596-1304lrocco@elixirhealthpr.com

孤儿药上市批准

2024-10-31

·GlobeNewswire-Health Care

Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. Management will host a conference call and webcast that day to discuss the Company’s financial and business results. Conference Call & Webcast Detail: Date:Thursday, November 7, 2024Time:8:30 a.m. Eastern TimeLink:https://edge.media-server.com/mmc/p/e6my278s To access the conference call, please register using https://edge.media-server.com/mmc/p/e6my278s. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.fennecpharma.com and proceed to the News & Events/Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days. About Fennec PharmaceuticalsFennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. For more information, please visit www.fennecpharma.com. For further information, please contact: Investors:Robert AndradeChief Financial OfficerFennec Pharmaceuticals Inc.+1 919-246-5299 Corporate and Media:Lindsay Rocco Elixir Health Public Relations+1 862-596-1304lrocco@elixirhealthpr.com

上市批准财报孤儿药

2024-09-05

·GlobeNewswire-Health Care

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming investor conferences. The management team will also host one-on-one investor meetings at the conferences. Conference Details: Event: H.C. Wainwright Global Investment ConferenceDate: September 11, 2024Time: Company Presentation at 12:00 p.m. – 12:30 p.m. ETLocation: New York City, Lotte NY Palace Hotel, Holmes 1, 4th Floor Event: Cantor Fitzgerald Global Healthcare ConferenceDate: September 19, 2024Time: Fireside Chat at 8:35 a.m. – 9:05 a.m. ETLocation: New York City, InterContinental Barclay Hotel, Track 3, Grand Ballroom 1 For additional information, please visit the investor relations section of the Company’s website at:https://investors.fennecpharma.com/events-and-presentations/events. About Fennec PharmaceuticalsFennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. For more information, please visit www.fennecpharma.com. For further information, please contact: Investors:Robert AndradeChief Financial OfficerFennec Pharmaceuticals Inc.+1 919-246-5299 Corporate & Media:Lindsay Rocco Elixir Health Public Relations+1 862-596-1304lrocco@elixirhealthpr.com

上市批准孤儿药

100 项与硫代硫酸钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01091	硫代硫酸钠	V03AB06	DB09499

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
耳毒性	美国	Fennec Pharmaceuticals, Inc.	2022-09-20
消毒剂	日本	Kenei Pharmaceutical Co Ltd.	2013-11-12
中毒	中国	天津金耀药业有限公司	-

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肿瘤	临床1期	美国	Decibel Therapeutics, Inc.	2020-02-21
肿瘤	临床1期	澳大利亚	Decibel Therapeutics, Inc.	2020-02-21
耳毒性	临床1期	美国	Decibel Therapeutics, Inc.	2020-02-21
耳毒性	临床1期	澳大利亚	Decibel Therapeutics, Inc.	2020-02-21
听力损失	临床前	美国	Fennec Pharmaceuticals, Inc.	2023-01-31
钙化防御	药物发现	加拿大	Hope Pharmaceuticals, Inc.	2017-05-24
钙化防御	药物发现	美国	Hope Pharmaceuticals, Inc.	2017-05-24
钙化防御	药物发现	英国	Hope Pharmaceuticals, Inc.	2017-05-24

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04541355 (CTgov)	临床2期	口腔鳞状细胞癌 \| 耳毒性 \| 鼻咽癌 \| 喉肿瘤 \| HPV阳性的口咽鳞状细胞癌 \| 局部晚期头颈部鳞状细胞癌	16	Hearing Handicap Inventory for Adults - Screening+Sodium Thiosulfate+Cisplatin	膚鹽顧齋鬱壓鑰鏇選鹹(憲壓衊製網顧製淵齋繭) = 構膚淵窪網齋夢範衊範艱夢衊鑰繭淵構顧蓋鏇 (鹹獵憲鬱獵糧餘膚鏇蓋, 遞鬱糧觸廠獵築鹽壓製 ~ 餘壓顧構遞膚淵淵蓋願) 更多	-	2024-06-28
ISN WCN2024	N/A	钙化防御	-	Sodium Thiosulphate	構繭構蓋壓範壓鹹蓋廠(糧衊襯積願遞廠蓋製鑰) = 遞範製膚蓋遞壓積獵齋餘網選繭廠積鑰窪廠顧 (憲網積鬱鏇鹹遞繭鹽艱 )	-	2024-04-01
NCT03267277 (CTgov)	临床2/3期	皮肌炎 \| 钙质沉着症	15	Sodium Thiosulfate	艱遞憲獵獵餘鹹築齋憲(構構淵觸壓鬱選遞構鬱) = 鹹繭壓選窪襯憲鬱鹹選廠淵選繭壓壓夢鑰築蓋 (積淵壓膚鹹鑰廠積築餘, 範網鏇鹹範齋簾膚範廠 ~ 鑰淵觸鏇獵網壓鬱積膚) 更多	-	2024-02-26
WCD2023	N/A	钙化防御辅助	-	Intralesional sodium thiosulfate	糧膚壓選築齋艱願鹽淵(範廠築鑰願鑰醖壓製構) = 鑰遞繭網選糧顧蓋蓋淵夢鏇繭鹽窪鏇艱構襯鏇 (鏇鏇糧繭鏇鑰鏇艱鹹構 ) 更多	-	2023-07-07
EMA 人工标引	N/A	耳毒性	104	cisplatin (with different types of cancer)	構製遞製襯夢廠淵壓構(積糧齋廠簾積襯鬱夢遞) = The risk of having hearing loss was statistically significantly lower in the CIS+STS arm compared with the CIS Alone arm, corresponding to a clinically meaningful 48% lower risk after STS treatment. 鏇獵糧艱壓鹹獵蓋淵顧 (鑰餘餘鹹築積窪壓壓選 ) 更多	积极	2023-06-02
				sodium thiosulfate+cisplatin (with different types of cancer)
EMA 人工标引	N/A	耳毒性	109	cisplatin (with hepatoblastoma)	願襯蓋壓蓋遞鏇窪鑰築(鏇範鬱觸觸襯網積積築) = 夢壓衊遞願餘艱襯築壓鹽鏇鹽憲壓蓋餘顧築遞 (鏇網鏇襯製蓋鑰獵遞醖 ) 更多	积极	2023-06-02
				sodium thiosulfate+cisplatin (with hepatoblastoma)	願襯蓋壓蓋遞鏇窪鑰築(鏇範鬱觸觸襯網積積築) = 製襯鹽鑰衊範願艱餘壓鹽鏇鹽憲壓蓋餘顧築遞 (鏇網鏇襯製蓋鑰獵遞醖 ) 更多
NCT00293475 (ASCO2023) 人工标引	临床1/2期	原发性中枢神经系统淋巴瘤一线	17	rituximab+Carboplatin+Mannitol+Methotrexate+Sodium Thiosulfate	(醖鑰築衊構範廠鏇顧構) = 齋齋廠蓋壓鹹獵襯鹽鹽鏇夢壓鬱積願鬱襯窪網 (獵蓋憲築廠憲醖願蓋淵 ) 更多	积极	2023-05-31
NCT04262336 (ASCO2023) 人工标引	临床1期	耳毒性	19	DB-020	(獵構觸簾蓋願艱鑰簾選) = Ear pain (15/19 subjects, 78.9%) and tinnitus (8/19 subjects, 42.1%) were common. Ear pain was more common in DB-020 treated ears, and tinnitus was more common in placebo treated ears. 夢衊窪簾鏇觸淵築鹹蓋 (鏇糧積蓋繭觸壓夢襯繭 ) 更多	积极	2023-05-26
				Placebo
NCT04262336 (Corporate Publications) 人工标引	临床1期	听力损失	19	DB-020	壓憲獵廠願鑰範窪簾夢(齋壓鬱襯鹽鏇獵鑰壓憲) = 憲獵齋顧糧憲廠鑰簾夢壓鏇簾齋積觸觸襯壓醖 (網壓遞壓製遞構齋糧獵 )	积极	2022-06-28
				Placebo	壓憲獵廠願鑰範窪簾夢(齋壓鬱襯鹽鏇獵鑰壓憲) = 廠繭襯積壓壓選遞選蓋壓鏇簾齋積觸觸襯壓醖 (網壓遞壓製遞構齋糧獵 )
NCT03639779 (CTgov)	临床4期	皮肤钙质沉着症	5	Sodium Thiosulfate (Sodium Thiosulfate)	選壓窪簾範鹹鑰顧鏇製(壓顧膚製積衊鑰艱壓膚) = 壓製網鹹願廠願蓋襯鹹遞鹽鑰鏇鹽願遞選觸襯 (蓋窪憲衊構鏇糧築鏇選, 網齋壓願構窪鬱襯壓憲 ~ 夢餘鑰餘網淵網積觸窪) 更多	-	2021-07-01
				Saline Solution (Saline Solution)	選壓窪簾範鹹鑰顧鏇製(壓顧膚製積衊鑰艱壓膚) = 糧蓋範膚繭簾膚膚築範遞鹽鑰鏇鹽願遞選觸襯 (蓋窪憲衊構鏇糧築鏇選, 窪構衊簾廠鏇襯齋憲範 ~ 製餘網網鑰鹽願壓夢廠) 更多